Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Clinical trial NCT05145010 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05145010
- Sponsor
- QED Therapeutics, a BridgeBio company
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-06
- Primary completion
- 2031-12-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.